Business Description

Amphastar Pharmaceuticals Inc. develops, markets, and sells technically difficult and proprietary injectable, intramuscular, and intranasal product lines. The company is divided into Finished Pharmaceutical Products (API) and Active Pharmaceutical Ingredients Products (API). The Finished Pharmaceutical Products segment produces, markets, distributes, and markets Primatene Mist and other critical care drugs. Active Pharmaceutical Ingredients Products manufactures and distributes porcine and human insulin. The company was founded on February 29, 1996, by Zi-Ping Luo, and Yong Feng Zhang, and has its headquarters in Rancho Cucamonga (CA).

Key Financials

Revenue (US$ Mn):

 

• Amphastar Pharmaceuticals Inc’s annual revenue for 2021 was US$ 438 Mn, a 25.16% increase from 2020
• The annual revenue generated by Amphastar Pharmaceuticals Inc in 2020 was US$ 350 Mn

 

Operating Income (US$ Mn):

 

• US$ 14 Mn was Amphastar Pharmaceuticals Inc’s operating income in 2021, a 125.4% increase from 2020 figures
• Amphastar Pharmaceuticals Inc indexed a -89.53% decrease in operating incomes from 2019, amounting to US$ 6 Mn in 2020
• Amphastar Pharmaceuticals Inc generated an operating income of US$ 60 Mn in 2019

 

Net Income (US$ Mn):

 

• US$ 63 Mn was the net income generated by Amphastar Pharmaceuticals Inc in 2021
• Amphastar Pharmaceuticals Inc’s net income for 2020 was US$ 1 Mn, a -97.83% decrease from 2019

 

Operating Margin %:

 

• Amphastar Pharmaceuticals Inc’s operating margin for 2021 was 3%, a 77.78% increase from 2020
• The operating margin generated by Amphastar Pharmaceuticals Inc in 2020 was 2%

 

Gross Margin %:

 

• 14% was Amphastar Pharmaceuticals Inc’s gross margin in 2021, a 7050% increase from 2020 figures
• Amphastar Pharmaceuticals Inc indexed a -98.59% decrease in gross margins from 2019, amounting to % in 2020
• Amphastar Pharmaceuticals Inc generated a gross margin of 14% in 2019

 

SWOT Analysis

Strengths